Please login to the form below

Not currently logged in
Email:
Password:

23andMe names privacy officer and corporate counsel

Kate Black joins from the US Department of Health and Human Services

edit-23andMe-Kate-BlackPersonal genetics firm 23andMe has appointed Kate Black as privacy officer and corporate counsel.

As a member of the legal and regulatory team, Black will be responsible for overseeing, updating and enhancing the company's privacy and consent policies for customers in the US and further afield.

Commenting on her appointment, Black said: “The potential impact that 23andMe can have on both individual health and the entire healthcare industry is profound.

“In appropriately leveraging the 23andMe database, we can significantly advance healthcare delivery, but we will not succeed unless we approach it with the utmost concern about protecting customer privacy and building customer trust.”

Black joins from the US Department of Health and Human Services, where she worked as a federal regulatory and interoperability policy analyst in the office of the national coordinator for health information technology.

She has also served as health privacy counsel for the Center for Democracy and Technology in San Francisco and has additionally worked on health technology policy initiatives at the Office of Science and Technology at the White House.

Kathy Hibbs, chief legal and regulatory affairs officer at 23andMe whom Black reports to, added: “Last year, our company committed to hiring a private officer to help us ensure that our privacy and consent policies best complement our philosophy on the importance of customer choice and empowerment.

“While we have always had a team dedicated to this effort, we are thrilled to have Kate take a leadership role at 23andMe.”

11th March 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics